These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 34484217)

  • 1.
    Yaegashi LB; Baldavira CM; Prieto TG; Machado-Rugolo J; Velosa APP; da Silveira LKR; Assato A; Ab'Saber AM; Falzoni R; Takagaki T; Silva PL; Teodoro WR; Capelozzi VL
    Front Immunol; 2021; 12():714230. PubMed ID: 34484217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low PD-1 Expression in Cytotoxic CD8
    Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
    Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
    [No Abstract]   [Full Text] [Related]  

  • 3. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
    Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
    J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
    Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
    Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes in PD-L1 expression and CD8
    Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
    Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer.
    Parra ER; Jiang M; Machado-Rugolo J; Yaegashi LB; Prieto T; Farhat C; de Sá VK; Nagai MA; de Lima VCC; Takagaki T; Terra R; Fabro AT; Capelozzi VL
    Arch Pathol Lab Med; 2020 Oct; 144(10):1234-1244. PubMed ID: 32150457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
    Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
    Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer.
    Wang L; Yang H; Dorn P; Berezowska S; Blank F; Wotzkow C; Marti TM; Peng RW; Harrer N; Sommergruber W; Kocher GJ; Schmid RA; Hall SRR
    EBioMedicine; 2021 Nov; 73():103664. PubMed ID: 34740105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer.
    Yan X; Jiao SC; Zhang GQ; Guan Y; Wang JL
    Cancer Gene Ther; 2017 Feb; 24(2):57-63. PubMed ID: 28084319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
    Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
    Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
    J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8
    Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
    Front Immunol; 2021; 12():680973. PubMed ID: 34122444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-Associated Fibroblasts Accelerate Malignant Progression of Non-Small Cell Lung Cancer via Connexin 43-Formed Unidirectional Gap Junctional Intercellular Communication.
    Luo M; Luo Y; Mao N; Huang G; Teng C; Wang H; Wu J; Liao X; Yang J
    Cell Physiol Biochem; 2018; 51(1):315-336. PubMed ID: 30453281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial interaction and functional status of CD68
    Liu X; Zhang Z; Yuan J; Yu J; Chen D
    Front Immunol; 2024; 15():1396719. PubMed ID: 38799432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC.
    Schulze AB; Schmidt LH; Heitkötter B; Huss S; Mohr M; Marra A; Hillejan L; Görlich D; Barth PJ; Rehkämper J; Evers G
    Thorac Cancer; 2020 Jan; 11(1):120-129. PubMed ID: 31760702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.
    Kilvaer TK; Rakaee M; Hellevik T; Østman A; Strell C; Bremnes RM; Busund LT; Dønnem T; Martinez-Zubiaurre I
    PLoS One; 2018; 13(2):e0192157. PubMed ID: 29415055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.